Can MSN’s fight for generic Cabometyx affect entry of the generics who already settled with Exelixis?

Zachary Silbersher

I previously blogged several times about Exelixis’ patent fight to delay entry of MSN’s generic formulation for Cabometyx. Since that time, a number of additional generics have sought to gain entry. To date, Exelixis has settled with most of the generics for Cabometyx by granting them entry in January 2031. MSN, by contrast, has yet to settle, and continues to litigate against Exelixis. How will MSN’s fight affect entry of the other generics who have already settled?

MSN is a first-filer (or “first applicant”), which means it was the first generic manufacturer to file an ANDA for Cabometyx. Under the Hatch-Waxman statute, as a first applicant, MSN could be entitled to 180 days of exclusivity to distribute its generic without competition from any other generics.

In August 2026, the Federal Circuit upheld the validity of three patents previously asserted against MSN, including the '439, '440 and ‘015 patents. Given that holding, MSN is blocked from entry until at least January 2030 when these patents are scheduled to expire.

MSN is also still litigating at least one patent for which it filed a Paragraph IV certification, namely, U.S. Patent No. 12,128,039, which does not expire until February 2032. The other generics, however, who are not “first applicants,” have already settled for entry January 2031. Thus, if MSN settles for the same or later date the other generics, will that push back entry by the other generics given that MSN is technically a “first applicant”? 

The Hatch-Waxman Act provides that approval of ANDAs cannot be less than 180 days before approval of the ANDA for a first applicant. See 21 U.S.C. § 355(j)(5)(B)(iv)(I). In other words, brands and generics cannot contract around the statutory restrictions on FDA approval of ANDAs. (Other commentators have concurred in this analysis. See here at 5 and 7.) Given this, if MSN agrees to an entry date that is equal to or later than the other generics, that will in theory push back entry of those later generics by 180 days.

This assumes that MSN has not relinquished or forfeited its first-applicant status. Generics can forfeit or lose first-applicant status for a variety of reasons. One reason a first-applicant could forfeit their first-applicant status is if it fails to market its generic drug within 75 days of FDA approval unless a Hatch-Waxman litigation remains pending against that first-applicant. See 21 U.S.C. § 355((j)(5)(D)(i)(I). Thus, although MSN’s drug has received approval, pending litigation with respect to the ‘039 patent should preclude its forfeiture of first-applicant status.

Given all this, it likely makes sense for MSN to continue to litigate the '039 patent because. If it wins, it can enter as early as January 2030, which will be more than six months (180 days) before the other generics who have already settled for 2031.

 At the same time, if MSN does prevail in its litigation against the ‘039 patent, that could in theory permit it to enter by January 2030, i.e., when the '439, '440 and ‘015 patents. Although Exelixis already settled with other generics for January 2031, those generics may be able to enter sooner than that. On the one hand, they could not likely enter at the same time as MSN, but would have to wait six months after MSN’s entry. On the other hand, most settlement agreements for Hatch-Waxman litigation typically include an acceleration clause that permits the generic to enter soon if certain events occur, such as a patent blocking their entry is invalidated or another generic secures an earlier entry date. That means, if MSN beats the ‘039 patent, there is a universe where MSN enters in January 2030, and other generics enter  in mid-2030. Much is therefore riding on trial over the ‘039 patent.

Next
Next

Can Axsome Therapeutic’s patent-thicket block Apotex’s generic Symbravo?